Journeying into Psilocybin with Dr. Alan Davis
Life, Death & The Space Between with Dr. Amy Robbins
Dr. Amy Robbins
4.8 • 585 Ratings
🗓️ 30 September 2019
⏱️ 30 minutes
🧾️ Download transcript
Summary
We’re diving into our second episode with Dr. Alan Davis, an Assistant Professor of Social Work at The Ohio State University and an Adjunct Assistant Professor in the Psychedelic Research Unit at Johns Hopkins University.
“The Science of Psychedelics” was Part 1 from last week, so if you need a bit of background knowledge on the science of psychedelics and the research involved, check ut that episode first.
This week in Part 2, “Journeying with Psilocybin” we are focused on the clinical practice and what the medical experience is like for psychedelic study participants.
We discuss...
- What the experience looks like for participants in the studies
- The co-creation of the mystical and insightful experience to create a therapeutic and healing experience
- If anyone has compared the experiences of people who have been treated in the study with people who have experienced their own spiritual or mystical experiences such as a Near Death Experience
- Prognosis for patient post-study
- How the world could be different if everyone could experience this vs. just those who have a psychiatric diagnosis
FOLLOW DR AMY ROBBINS
http://www.instagram.com/dramyrobbins
Hosted on Acast. See acast.com/privacy for more information.
Transcript
Click on a timestamp to play from that location
| 0:00.0 | Hi, I'm Dr. Amy Robbins and welcome to life, death, and the Space Between Podcast. |
| 0:10.0 | I'm a licensed clinical psychologist and medium, and here we explore life, death, consciousness, |
| 0:17.2 | and what it all means. Today, we have Dr. Alan K. Davis back on the show. |
| 0:23.5 | Last week, Dr. Davis spoke with us about the science of psychedelics. |
| 0:28.8 | And today, Dr. Davis is back to talk with us about the clinical practice and applications |
| 0:35.2 | of psychedelics. |
| 0:36.7 | So welcome back. Thank you. Happy to be back. |
| 0:41.4 | So let's dig in to what the research actually looks like. Can you walk me through what the |
| 0:49.8 | experience of someone going through your clinical study would do and how that would look for |
| 0:56.5 | them? |
| 0:57.2 | Sure. |
| 0:57.7 | So it is certainly an extensive process, as you might imagine, to get enrolled in a, for any |
| 1:05.9 | really, excuse me, really for any clinical trial, but certainly for a clinical trial that is |
| 1:10.6 | administering a schedule one substance, meaning that the hurdles require even to just conduct the |
| 1:17.4 | study are enormous, not only financially and from a time-consuming standpoint, but both |
| 1:24.3 | FDA and the DEA, as well as the institutional IRB, all have to agree and be on the same page before it ever gets started. |
| 1:33.1 | But because of that, that means that every single person that eventually enrolls in the study has to go through an extensive screening process in order to have them both meet criteria, meaning that, you know, if we're doing |
| 1:47.1 | a study for people with depression, we have to make sure they have depression and we have to |
| 1:50.4 | make sure they don't have any other things that might get in the way of us treating the depression, |
| 1:56.1 | which is a kind of a thing in all in itself trying to find someone who only has one kind of |
| 2:01.7 | problem. And then also we have to do an extensive exclusion of different things. So the current |
| 2:08.5 | study that we have gone right now for depression, we also have a neuroimaging component. And so |
... |
Please login to see the full transcript.
Disclaimer: The podcast and artwork embedded on this page are from Dr. Amy Robbins, and are the property of its owner and not affiliated with or endorsed by Tapesearch.
Generated transcripts are the property of Dr. Amy Robbins and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.
Copyright © Tapesearch 2026.